



NDA 20-132/S-018

GlaxoSmithKline  
Attention: Christopher J. Stotka, PharmD  
Associate Director, Regulatory Affairs  
PO Box 13398  
Five Moore Drive  
Research Triangle Park, NC 27709

Dear Dr. Stotka:

Please refer to your supplemental new drug application dated February 26, 2004, received March 1, 2004, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Imitrex (sumatriptan) tablets.

This "Changes Being Effected" supplemental new drug application provides for changes to the Patient Information section of labeling.

We have completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the submitted labeling (package insert submitted February 26, 2004, patient package insert submitted February 26, 2004, immediate container and carton labels submitted February 26, 2004).

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-132.S-018." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410  
FDA  
5600 Fishers Lane  
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Lana Chen, Regulatory Project Manager, at (301) 594-5529.

Sincerely,

*{See appended electronic signature page}*

Russell Katz, M.D.  
Director  
Division of Neuropharmacological Drug Products  
Office of Drug Evaluation I  
Center for Drug Evaluation and Research

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Russell Katz  
6/17/04 07:22:05 AM